8/8/2017 AML induction regimens - UpToDate

Official reprint from UpToDate

2017 UpToDatewww.uptodate.com

Chemotherapy induction regimens for acute myeloid leukemia

Drugs Dosing Comments

Cytarabine Cytarabine: 100 to 200 mg/m 2 daily as a continuous "Standard 7+3" induction regimen resulting in approximately 60 to 80 percent
plus infusion for 7 days; Daunorubicin: 60 to 90 mg/m 2 remission rate and acceptable toxicity in patients under 60 years old
daunorubicin intravenous push on each of the first 3 days of
treatment

Cytarabine Cytarabine: 1 to 3 g/m 2 twice daily for a total of 12 Yields a 90 percent remission rate; however, substantial toxicity precludes
(HDAC) doses; Daunorubicin: 45 mg/m 2 intravenous push for postremission therapy in a high proportion of patients
plus 3 days following cytarabine
daunorubicin

Cytarabine Cytarabine: 100 to 200 mg/m 2 daily as a continuous Has produced a greater remission rate (88 versus 70 percent) than
plus infusion for 7 days; Idarubicin: 12 to 13 mg/m 2 IV cytarabine/daunorubicin in younger patients; appears superior to daunorubicin in
idarubicin push on each of first 3 days of treatment patients with hyperleukocytosis; overall survival not clearly superior to "standard"
regimen

Overview of common induction therapy regimens for acute myeloid leukemia in younger adults.

HDAC: high dose cytarabine.

Graphic 78251 Version 4.0

https://www.uptodate.com/contents/image/print?imageKey=HEME%2F78251&topicKey=HEME%2F4525&rank=1~150&source=see_link&search=cytarabine%20damage%20fertility 1/1